Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.
COVID-19
SARS-Cov2
hydroxychloroquine
intensive care
pharmacokinetic
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
19 11 2020
19 11 2020
Historique:
received:
01
04
2020
accepted:
03
04
2020
pubmed:
8
4
2020
medline:
15
12
2020
entrez:
8
4
2020
Statut:
ppublish
Résumé
Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations. Pharmacokinetic studies are therefore needed to define the optimal dosing regimen.
Identifiants
pubmed: 32255489
pii: 5816960
doi: 10.1093/cid/ciaa394
pmc: PMC7184449
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2227-2229Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.